Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens
Authors
Keywords
-
Journal
VIRCHOWS ARCHIV
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-08
DOI
10.1007/s00428-020-02818-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens
- (2018) Soomin Ahn et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer
- (2018) Gustav Stålhammar et al. HISTOPATHOLOGY
- Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer
- (2018) Lutfi Alfarsi et al. HISTOPATHOLOGY
- Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis
- (2017) Marina Gándara-Cortes et al. VIRCHOWS ARCHIV
- Diversity index as a novel prognostic factor in breast cancer
- (2017) Yul Ri Chung et al. Oncotarget
- Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume
- (2016) C. M. Focke et al. ANNALS OF SURGICAL ONCOLOGY
- Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours
- (2016) Cornelia M Focke et al. HISTOPATHOLOGY
- Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma
- (2016) Arvydas Laurinavicius et al. VIRCHOWS ARCHIV
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
- (2015) Xiaosong Chen et al. BMC CANCER
- A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data
- (2015) Benoit Plancoulaine et al. VIRCHOWS ARCHIV
- Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
- (2014) Yoshiya Horimoto et al. BMC CANCER
- Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values
- (2014) Gábor Cserni et al. BREAST
- Assessment of the Ki67 labeling index: a Japanese validation ring study
- (2014) Naoki Niikura et al. Breast Cancer
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer
- (2013) Xiaosong Chen et al. BMC CANCER
- High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer
- (2013) Carmen Criscitiello et al. BREAST
- Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
- (2013) G. von Minckwitz et al. CLINICAL CANCER RESEARCH
- Tailoring Adjuvant Treatments for the Individual Patient with Luminal Breast Cancer
- (2013) Elisabetta Munzone et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists
- (2012) Zsuzsanna Varga et al. PLoS One
- Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer
- (2012) Marcos Desidério Ricci et al. Revista da Associacao Medica Brasileira
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
- (2011) Quinci Romero et al. BMC CANCER
- Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer
- (2011) Z. Bago-Horvath et al. CLINICAL CANCER RESEARCH
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
- (2011) Jack Cuzick et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Histopathological criteria and selection algorithms for BRCA1 genetic testing
- (2009) Dorothea Gadzicki et al. CANCER GENETICS AND CYTOGENETICS
- Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
- (2009) Judith Hugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
- (2008) R. Stuart-Harris et al. BREAST
- Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer
- (2008) A. Rody et al. BREAST CANCER RESEARCH AND TREATMENT
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started